Last reviewed · How we verify

UConn Health — Portfolio Competitive Intelligence Brief

UConn Health pipeline: 2 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Ketorolac Tromethamine Injection Ketorolac Tromethamine Injection marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) Pain Management / Anesthesia
Dutasteride Capsules Dutasteride Capsules marketed 5-alpha reductase inhibitor 5-alpha reductase (type 1 and type 2) Urology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Actavis Inc. · 1 shared drug class
  2. Amneal Pharmaceuticals, LLC · 1 shared drug class
  3. Amzell · 1 shared drug class
  4. Assaf-Harofeh Medical Center · 1 shared drug class
  5. Azienda USL Reggio Emilia - IRCCS · 1 shared drug class
  6. Bausch & Lomb Incorporated · 1 shared drug class
  7. Bayer · 1 shared drug class
  8. Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for UConn Health:

Cite this brief

Drug Landscape (2026). UConn Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/uconn-health. Accessed 2026-05-16.

Related